Patents by Inventor Shangwu Wang

Shangwu Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant adenovirus useful for treating malignancy over-expressing proto-oncogene neu/erb B2
    Patent number: 8920811
    Abstract: A recombinant adenovirus is applied for treating malignancy of over-expressing proto-oncogene neu/erbB2, wherein an expression cassette, which co-expresses the humanized monoclonal antibody variable region gene of anti proto-oncogene neu/erbB2 and the Mda-7/IL-24 gene, is inserted into E1 deletion region of the recombinant adenovirus. The recombinant adenovirus effectively treats the malignancy of overexpressing proto-oncogene neu/erbB2 without damaging normal cells, such that the recombinant adenovirus is able to be used for the gene therapy of malignancy tumors over-expressing proto-oncogene neu/erbB2.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: December 30, 2014
    Inventor: Shangwu Wang
  • Recombinant adenovirus target-oriented co-expressing human p53 and p53aip1
    Publication number: 20120009587
    Abstract: A recombinant adenovirus target-oriented co-expressing human p53 variant and p53AIP1 is disclosed, which is inserted an expression cassette co-expressing human p53 variant and p53AIP1 in E1 deletion region of the adenovirus. The expression cassette consists of tumor specific promoter, human p53 variant, internal ribosome entry site (IRES), human p53AIP1, and SV40.
    Type: Application
    Filed: August 31, 2007
    Publication date: January 12, 2012
    Inventors: Shangwu Wang, Yanan Zhu
  • RECOMBINANT ADENOVIRUS USEFUL FOR TREATING MALIGNANCY OVER-EXPRESSING PROTO-ONCOGENE NEU/ERB B2
    Publication number: 20100221811
    Abstract: A recombinant adenovirus is applied for treating malignancy of over-expressing proto-oncogene neu/erbB2, wherein an expression cassette, which co-expresses the humanized monoclonal antibody variable region gene of anti proto-oncogene neu/erbB2 and the Mda-7/IL-24 gene, is inserted into E1 deletion region of the recombinant adenovirus. The recombinant adenovirus effectively treats the malignancy of overexpressing proto-oncogene neu/erbB2 without damaging normal cells, such that the recombinant adenovirus is able to be used for the gene therapy of malignancy tumors over-expressing proto-oncogene neu/erbB2.
    Type: Application
    Filed: April 2, 2008
    Publication date: September 2, 2010
    Inventor: Shangwu Wang